Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to "Strong-Buy" at Baird R W

Baird R W upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX - Free Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

Several other analysts also recently commented on CPRX. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target for the company. Robert W. Baird initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday. They issued an "outperform" rating and a $28.00 price target for the company. HC Wainwright upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. StockNews.com cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 11th. Finally, Bank of America reissued a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.25.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX traded down $0.16 during trading on Monday, hitting $22.90. 592,293 shares of the company were exchanged, compared to its average volume of 1,320,317. The stock has a market capitalization of $2.73 billion, a P/E ratio of 19.41, a PEG ratio of 3.46 and a beta of 0.80. Catalyst Pharmaceuticals has a 12-month low of $13.12 and a 12-month high of $24.64. The firm's 50 day moving average price is $22.07 and its 200-day moving average price is $20.87.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company's stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock worth $1,754,140 over the last ninety days. 11.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $27,000. GAMMA Investing LLC lifted its position in Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals during the third quarter valued at approximately $50,000. Larson Financial Group LLC lifted its position in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $65,000. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.